Opko Health - Der nächste Blockbuster (Seite 234)
eröffnet am 10.12.13 19:42:20 von
neuester Beitrag 03.04.24 17:56:57 von
neuester Beitrag 03.04.24 17:56:57 von
Beiträge: 3.048
ID: 1.189.336
ID: 1.189.336
Aufrufe heute: 0
Gesamt: 261.065
Gesamt: 261.065
Aktive User: 0
ISIN: US68375N1037 · WKN: A0MUUJ · Symbol: XCY
1,2600
USD
+3,28 %
+0,0400 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
05.03.24 · globenewswire  |
27.02.24 · globenewswire |
22.02.24 · globenewswire |
09.01.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9000 | +305,04 | |
| 0,6080 | +26,25 | |
| 6,0000 | +25,00 | |
| 56,69 | +20,00 | |
| 0,6400 | +18,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,6000 | -12,16 | |
| 8,5000 | -15,00 | |
| 0,7300 | -18,59 | |
| 92,06 | -19,84 | |
| 2,7280 | -29,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
Dafür schon was im reg. Handel- für einen schwachen Freitag ganz gut bislang. Wenn man sieht, wo sie herkommt...ist schon noch Platz nach oben
Heute noch nix im Pre Market los... Da sind alle gespannt wie es heut früh bzw nachmittags bei uns weiter geht. Ich bin auch sehr gespannt.
Video-Interview mit Jon Cohen von OPKO Health's BioReference Labs
WHY OPKO HEALTH SHARES WERE UP 10% TODAY
The company is rolling out a new COVID-19 testing program for businesses.
What happened
After announcing it has launched a COVID-19 screening program to help employers make return-to-work decisions for employees, OPKO Health (NASDAQ:OPK) saw its shares close the day up more than 10% on Thursday.
So what
OPKO Health's BioReference Labs has been assisting healthcare providers with COVID-19 testing services since mid-March. On Monday, management expanded its COVID-19 product platform with the launch of an antibody test that can determine if someone has been exposed to the virus, and on Wednesday, the healthcare company unveiled services designed to inform business decisions relating to employees.
Specifically, its BioReference employer solution will allow employees to register for antibody testing online. It also provides for on-site testing and processing, with online access to testing results. BioReference is also offering pop-up testing sites that businesses can use, with the first of these locations opening on Friday in Livingston, New Jersey.
The move positions the company to capture a growing share of what is becoming a significant opportunity: increasing demand for testing services. Since March, BioReference Labs has performed hundreds of thousands of tests, and its capacity has reached 35,000 tests daily.
Now what
OPKO's revenue was $211.5 million in the first quarter, which was down 4.9% year over year because early testing capacity wasn't able to offset declining lab-services demand from doctor-office visits caused by shelter-in-place orders. It's unclear if COVID-19 testing, including antibody testing, will be able to overcome the headwind this quarter, but management has said it will soon be able to process 400,000 antibody tests per day.
An increase in COVID-19 business is particularly important to OPKO Health, because it posted losses of $59.1 million last quarter, and it's arguably financially hamstrung given the company only had $35 million in cash on its balance sheet exiting March. The company does have wiggle room courtesy of a $100 million credit facility from its founder, Phillip Frost, but it could certainly benefit if COVID-19 testing demand can keep it from tapping that financing.
https://www.fool.com/investing/2020/05/14/why-opko-health-sh…
The company is rolling out a new COVID-19 testing program for businesses.
What happened
After announcing it has launched a COVID-19 screening program to help employers make return-to-work decisions for employees, OPKO Health (NASDAQ:OPK) saw its shares close the day up more than 10% on Thursday.
So what
OPKO Health's BioReference Labs has been assisting healthcare providers with COVID-19 testing services since mid-March. On Monday, management expanded its COVID-19 product platform with the launch of an antibody test that can determine if someone has been exposed to the virus, and on Wednesday, the healthcare company unveiled services designed to inform business decisions relating to employees.
Specifically, its BioReference employer solution will allow employees to register for antibody testing online. It also provides for on-site testing and processing, with online access to testing results. BioReference is also offering pop-up testing sites that businesses can use, with the first of these locations opening on Friday in Livingston, New Jersey.
The move positions the company to capture a growing share of what is becoming a significant opportunity: increasing demand for testing services. Since March, BioReference Labs has performed hundreds of thousands of tests, and its capacity has reached 35,000 tests daily.
Now what
OPKO's revenue was $211.5 million in the first quarter, which was down 4.9% year over year because early testing capacity wasn't able to offset declining lab-services demand from doctor-office visits caused by shelter-in-place orders. It's unclear if COVID-19 testing, including antibody testing, will be able to overcome the headwind this quarter, but management has said it will soon be able to process 400,000 antibody tests per day.
An increase in COVID-19 business is particularly important to OPKO Health, because it posted losses of $59.1 million last quarter, and it's arguably financially hamstrung given the company only had $35 million in cash on its balance sheet exiting March. The company does have wiggle room courtesy of a $100 million credit facility from its founder, Phillip Frost, but it could certainly benefit if COVID-19 testing demand can keep it from tapping that financing.
https://www.fool.com/investing/2020/05/14/why-opko-health-sh…
Trading Spotlight
Antwort auf Beitrag Nr.: 63.687.010 von Malecon am 14.05.20 22:39:27414000 Stück. Merken wir uns mal die Zahl und schauen in ein paar Tagen nach, wieviel Mr. Frost gekauft hat. 😉
Überhaupt haben heute einige Großinvestoren zugeschlagen:
Im nachbörslichen Handel ist es normalerweise tote Hose, aber heute kauft jemand etwas größere Pakete.
Antwort auf Beitrag Nr.: 63.685.834 von Hastdunicht am 14.05.20 21:20:18in der mitte der usa ? da sind alles trump-wähler die glauben nicht an den virus denn das ist nur eine erfindung von bill gates,china,illuminaten .....
Opko Health – Consensus Indicates Potential 73.6% Upside
Opko Health with ticker code (OPK) now have 4 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 6 and 3 and has a mean target at 4.15. Given that the stocks previous close was at 2.39 this now indicates there is a potential upside of 73.6%.
https://www.directorstalkinterviews.com/opko-health-consensu…
Opko Health with ticker code (OPK) now have 4 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 6 and 3 and has a mean target at 4.15. Given that the stocks previous close was at 2.39 this now indicates there is a potential upside of 73.6%.
https://www.directorstalkinterviews.com/opko-health-consensu…
Durchsuchen
